Entries by CoratTx

TV report on COR-101

CORAT’s CEO Dr. Andreas Herrmann and CSO Dr. André Frenzel comment in international television on the start of clinical studies with CORAT Therapeutics SARS-CoV-2 neutralising antibody COR-101 against COVID-19 in hospitalized patients. The article can be viewed at the following link: COVID-19 Special: The challenge of developing a cure Source: Deutsche Welle Berlin

May 11, 2021 by

First hospitalized COVID-19 patient treated with the antibody drug candidate COR-101

Tübingen, Germany, 23.4.2021 – CORAT Therapeutics initiated a Phase Ib/II clinical trial evaluating the safety, tolerability, and efficacy of COR-101 in a total of 45 patients at five sites in Germany CORAT Therapeutics GmbH announced the start of a clinical trial with COR-101 for treatment of COVID-19 in hospitalized patients. The novel therapeutic antibody may […]

April 23, 2021 by

COR-101 approved for first clinical study

CORAT Therapeutics GmbH obtained regulatory authorization for clinical phase Ib/II trial with the SARS-CoV-2 neutralizing human antibody COR-101. The study (ClinicalTrials.gov ID: NCT04674566) is a randomized, double-blind, placebo-controlled, parallel-group, multicenter, first-in-human, phase Ib/II study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of COR-101 in hospitalized patients with moderate to severe COVID-19. We […]

March 16, 2021 by

Second financing round secured for the development of COR-101

A second financing round was closed with NBank Capital, the investment company of NBank. Additional investors came from the private sector in Braunschweig. CORAT Therapeutics is in close coordination with the regulatory authorities and expects the green light for the start of clinical testing shortly. “The development of a drug against Corona must not fail […]

January 12, 2021 by

Human SARS-CoV-2 neutralizing antibody COR-101 demonstrates high efficacy in a COVID-19 animal model and is ready to be used in clinical studies to treat COVID-19 patients

COR-101 decreased SARS-CoV-2 virus load in the lung by more than 99% COR-101 induced recovery after 2 days, compared to 7 days untreated CORAT Therapeutics GmbH today reports the successful conclusion of hamster disease model tests of their lead candidate COR-101 against COVID-19. It induced recovery of SARS-CoV-2 infected hamsters within two days. In contrast, […]

December 18, 2020 by

How human antibody COR-101 neutralizes the coronavirus SARS-CoV-2

Because SARS-CoV-2 is a novel virus, many people have not yet developed antibodies against the pathogen. Vaccines can protect healthy people, but they cannot cure people affected by COVID-19. Furthermore, not everyone responds to the vaccine. Passive immunisation by administering antibodies can help here for both, curing those people affected and prevent infection and/or onset […]

December 4, 2020 by

CORAT won the Durchstarter Award of the State of Lower Saxony

In an event with Economics Minister Dr. Althusmann, Dr. Sabine Johannsen, State Secretary for Science and Culture and Stefan Muhle, State Secretary in Lower Saxony’s Ministry of Economics, Labour, Transport and Digitisation, CORAT Therapeutics won this year’s startup Award „Durchstarterpreis“ for corona solutions of the State of Lower Saxony. Worldwide, hundreds of millions of people […]

December 2, 2020 by